The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

Journal: P.A. Herzen Journal of Oncology. 2017;6(3): 35‑43

DOI: doi: 10.17116/onkolog20176335-43

Read: 3693 times

Download PDF (RU)
Contact the author
Table of contents

INDIRECT TREATMENT COMPARISON OF DABRAFENIB PLUS TRAMETINIB VERSUS VEMURAFENIB PLUS COBIMETINIB IN PREVIOUSLY UNTREATED METASTATIC MELANOMA PATIENTS
INDIRECT TREATMENT COMPARISON OF DABRAFENIB PLUS TRAMETINIB VERSUS VEMURAFENIB PLUS COBIMETINIB IN PREVIOUSLY UNTREATED METASTATIC MELANOMA PATIENTS

To cite this article:

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. P.A. Herzen Journal of Oncology. 2017;6(3):35‑43. (In Russ.)
https://doi.org/doi: 10.17116/onkolog20176335-43

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Algazi AP, Soon CW, Daud AI. Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res. 2010;2:197-211.
  2. Finn L, Markovic SN, Joseph RW. Therapy for metastatic melanoma: the past, present, and future. BMC Med. 2012;10:23.doi:10.1186/1741-7015-10-23
  3. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004;150:179-185.
  4. American Cancer Society. Melanoma Skin Cancer. 2016. Accessed 20 Jul 2016. http://www.cancer.org/cancer/skincancer-melanoma/
  5. Erdmann F, Lortet-Tieulent J, Schüz J, Zeeb H, Greinert R, Breitbart EW, et al. International trends in the incidence of malignant melanoma 1953—2008-are recent generations at higher or lower risk? Int J Cancer. 2013;132:385-400.
  6. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-2147.
  7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
  8. Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-κB/Snail/RKIP/PTEN circuit. Genes Cancer. 2010;1:409-420.
  9. Nissan MH, Solit DB. The «SWOT» of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? Curr Oncol Rep. 2011;13:479-487.
  10. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239-1246.
  11. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
  12. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet. 2012;380:358-365.
  13. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366:207-215.
  14. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4:80-93.
  15. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4:94-109.
  16. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694-1703.
  17. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23:177-182.
  18. Carnahan J, Beltran PJ, Babij C, Le Q, Rose MJ, Vonderfecht S, et al. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther. 2010;9:2399-2410.
  19. Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol. 2012;30:316-321.
  20. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24:1691-1697.
  21. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867-1876.
  22. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26,Suppl.5:v126-v132.
  23. National Comprehensive Cancer Network. NCCN Guidelines Version 2.2015 -Melanoma. Accessed 20 Jul 2016. https://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf
  24. European Medicines Agency. EPAR summary for the public. Cotellic, cobimetinib. 2016. Accessed 20 Jul 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003960/WC500198615.pdf
  25. Food US, Administration D. FDA approves Cotellic as part of combination treatment for advanced melanoma. 2015. Accessed 20 Jul 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471934.htm
  26. Srivastava K, Amonkar MM, Ahuja A, Stapelkamp C, Swann S, Casey M, et al. Systematic review and indirect treatment comparison of dabrafenib and trametinib versus other treatments used in previously untreated metastatic melanoma patients. J Clin Exper Dermatol Res. 2015;6:294.
  27. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30-39.
  28. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683-691.
  29. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroyakovskiy D, et al. Two-year estimate of overall survival in COMBI-v, a randomized, openlabel, phase 3 study comparing the combination of dabrafenib and trametinib vs vemurafenib as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. European Cancer Congress, 25—29 September, 2015b, abstract 3301.
  30. Atkinson V, Larkin J, McArthur G, Ribas A, Ascierto P, et al. (2015b) Improved overall survival (OS) with cobimetinib (COBI) + vemurafenib (V) in advanced BRAF-mutated melanoma and biomarker correlates of efficacy. Presented at the annual meeting of the Society for Melanoma Research held November 6—9, 2015 in Boston, Massachusetts.
  31. Tang J, Zhang H, Yan J, Shao R. Indirect comparison of the efficacy and safety of gefitinib and cetuximab-based therapy in patients with advanced non-small-cell lung cancer. Mol Clin Oncol. 2015;3(1):145-150.
  32. Larkin JMG, Yan Y, McArthur GA, Ascierto PA, Liszkay G, et al. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J Clin Oncol. 2015;33(15,suppl):abstr 9006.
  33. European Medicines Agency. Cotellic, INN-Cobimetinib-Label. 2015.
  34. Dréno B, Ascierto PA, McArthur GA, Ribas A, Eng S, Hsu JJ, et al. Adverseevent (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: extended follow-up (f/u) of the phase III coBRIM study. American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA, 3—7 June 2016, abstract 9533. Accessed 20 July 2016. http://meetinglibrary.asco.org/content/165055-176
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.